

ATTORNEY DOCKET NO: HAMDI-001B  
TITLE: METHODS FOR INHIBITING CANCER & SCAR FORMATION  
SERIAL NO.: 10/712,423 FILED: NOVEMBER 13, 2003

**Certificate of Mailing under 37 CFR 1.8 or 37 CFR 1.10**


☒ I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

☐ I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail No. EL 988303652 US addressed to:

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 18, 2004


  
(Signature)

LINDA JOHNSON  
(Typed name of person signing certificate)

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.


1. TRANSMITTAL;
2. IDS COVER LETTER;
3. COPY OF ACKNOWLEDGEMENT RECEIPT;
4. PTO/SB/08B IN DUPLICATE;
5. FOUR (4) PRIOR ART REFERENCES;
6. CERTIFICATE OF MAILING; AND
7. RETURN RECEIPT POSTCARD.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 <b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/712,423
	Filing Date	NOVEMBER 13, 2003
	First Named Inventor	HAMDI K. HAMDI
	Art Unit	1614
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	HAMDI-001B


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	PTO/SB/08B WITH 4 PRIOR ART REFS.;
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	ACKNOWLEDGEMENT RECEIPT #55733;
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	CERT. MAIL; RETURN POSTCARD.
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MATTHEW A. NEWBOLES STETINA BRUNDA GARRED & BRUCKER
Signature	
Date	2/18/04

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date:

Typed or printed name	LINDA JOHNSON
Signature	
Date	2-18-04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Application No.: 10/712,423  
Attorney Docket: HAMDI-001B



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	HAMDI K. HAMDI ET AL.	)	Confirmation No.	9959
		)		
Serial No.:	10/712,423	)	Art Unit:	1614
		)		
Filed:	NOVEMBER 13, 2003	)	Examiner:	
		)		
For:	METHODS FOR INHIBITING	)		
	CANCER AND SCAR FORMATION	)		

---

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. SECTION 1.97**

MAIL STOP DD  
Commissioner for Patents  
P.O.Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97, the following Information Disclosure Statement is submitted as listed on form PTO/SB/08B enclosed herewith in duplicate. Copies of all disclosure documents are attached hereto for the Examiner's review. Please note that this is filed concurrently with one or more additional Information Disclosure Statements which were filed electronically on today's date. Attached are the Acknowledgement Receipts: reference EFS ID 55733.

No representation is made that the references disclosed herein legally constitute prior art, or that more relevant references are not available. The disclosure documents enclosed herewith and listed on the attached form (PTO/SB/08B) are printed in the English language and/or accompanied by and Abstract published in the English language.


The references listed herein, when taken alone or in combination, are not believed to disclose nor make obvious the invention as claimed in the subject application.

As these Information Disclosure Statements are being submitted before the stipulated three months from the filing date of the application and/or before the mailing

of a first Office Action, it is believed that no fee is required. If any additional fee is required, please charge Account Number 19-4330.


Respectfully submitted,

Date: 2/18/04

By: 

Customer No.: 007663

Matthew A. Newboles  
Registration No. 36,224  
STETINA BRUNDA GARRED & BRUCKER  
75 Enterprise, Suite 250  
Aliso Viejo, California 92656  
Telephone: (949) 855-1246



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 0

### Complete if Known

Application Number	10/712,423
Filing Date	NOVEMBER 13, 2003
First Named Inventor	HAMDI K. HAMDI, ET AL.
Group Art Unit	
Examiner Name	
Attorney Docket Number	HAMDI-001B

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		McCarty, Med. Hypothesis, Vol. 50(6), pp. 511-4 (abstract). 6/1998.	
		Visioli et al., Biochem. Biophys. Res. Commun., Vol. 247(1), pp. 60-4 (abstract), 6/09/1998.	
		de la Puerta et al., Biochem. Pharmacol., Vol. 57(4), pp. 445-9 (abstract), 2/15/1999.	
		Park et al., Chem Pharm Bull (Tokyo), Vol. 47(7), pp. 1029-31 (abstract), 7/1999.	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.